Table 3

Factors affecting long-term clinical outcomes.

(A) Factors affecting overall survival (OS)

	Univariate			Multivariate

	HR	95% CI	P	HR	95% CI	P
Age>60 vs. ≤60 yr	20.372	3.466–119.724	0.001	61.945	5.675–676.201	0.001
ECOG PS>1 vs. ≤1	10.429	2.851–38.155	<0.001	21.384	2.851–160.369	0.003
LDH, increased vs. normal	7.408	2.381–23.049	0.001	6.576	1.655–26.139	0.007
High ADC vs. low ADC	0.273	0.103–0.721	0.009	0.392	0.155–0.854	0.012
Size≥5 cm vs. <5 cm	2.694	0.931–7.794	0.067

(B) Factors affecting failure-free survival (FFS)

	Univariate			Multivariate

	HR	95% CI	P	HR	95% CI	P

Age>60 vs. ≤60 yr	4.227	1.597–11.192	0.004
ECOG PS>1 vs. ≤1	4.278	1.305–14.017	0.016	10.319	1.428–74.551	0.021
LDH, increased vs. normal	1.839	0.882–3.831	0.099
Enhancement, homogenous vs. non-homogenous	0.401	0.193–0.834	0.014
Necrosis, presence vs. absence	4.610	2.151–9.876	<0.001	6.372	1.609–25.235	0.008
High ADC vs. low ADC	0.432	0.210–0.888	0.022	0.226	0.065–0.792	0.020
T2-weighted imaging, hyperintense signal vs. isointense signal	0.289	0.128–0.650	0.003

Abbreviations: ADC, apparent diffusion coefficient; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; LDH, lactate dehydrogenase.

Blood Res 2020;55:99~106 https://doi.org/10.5045/br.2020.2020032